MIRA
INFORM REPORT
|
Report Date : |
07.05.2011 |
IDENTIFICATION DETAILS
|
Name : |
FABTECH TECHNOLOGIES INTERNATIONAL LIMITED (w.e.f 09.07.2010) |
|
|
|
|
Formerly Known
As : |
FABTECH TECHNOLOGIES INTERNATIONAL PRIVATE LIMITED |
|
|
|
|
Registered
Office : |
717, Janki Centre, Off Veera Desai Road, Andheri (W), Mumbai – 400053,
Maharashtra |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2010 |
|
|
|
|
Date of
Incorporation : |
20.11.1995 |
|
|
|
|
Com. Reg. No.: |
094603 |
|
|
|
|
Paid-up Capital
: |
Rs.27.700 millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24230MH1995PLC094603 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
MUMF02816C |
|
|
|
|
Legal Form : |
A Closely held Public Limited Liability Company |
|
|
|
|
Line of Business
: |
Manufacturer of clean room equipments, pre – fabricated panels and
injectable lines. |
|
|
|
|
No. of Employees : |
Information not divulged by management |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (45) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 772000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually Correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is an established company having satisfactory track. Trade relations
are reported as fair. Business is active. Payments are reported to be usually
correct and as per commitments. The company can be considered normal for business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – April 1, 2010
|
Country Name |
Previous Rating (31.12.2009) |
Current Rating (01.04.2010) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
INFORMATION DENIED BY
|
Name : |
Mr. Rupesh |
|
Designation : |
Accounts Department |
LOCATIONS
|
Registered Office : |
717, Janki Centre, Off Veera Desai Road, Andheri (W), Mumbai – 400053,
Maharashtra |
|
Tel. No.: |
91-22-66912900-08 |
|
Fax No.: |
91-22-66921555 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Head Office : |
615, Janki Centre, Off. |
|
Tel. No.: |
91-22-61592900 |
|
Fax No.: |
91-22-26730136/61592855 |
|
E-mail : |
|
|
|
|
|
Factory : |
Plot No.190/191 GIDC, Umargoan – 396171, |
|
Tel. No.: |
91-260-3092976/2560067/2562184 |
|
Fax No.: |
91-260-3092976/2560067/2562184 |
|
|
|
|
Branches 1 : |
Plot No. 11, Subba Rao Colony, Behind LBR House, |
|
Tel. No.: |
91-40-55227265 |
|
Fax No.: |
91-40-27716589 |
|
E-Mail : |
|
|
|
|
|
International Branches : |
Located at:
|
DIRECTORS
AS ON 30.09.2010
|
Name : |
Mr. Aasif Ahsan Khan |
|
Designation : |
Director |
|
Address : |
604, D-15, Indira Darshan –II, Swami Samarth Nagar, Andheri (W),
Mumbai – 400053, Maharashtra, India. |
|
Date of Birth/Age : |
13.09.1968 |
|
Date of Appointment : |
20.11.1995 |
|
|
|
|
Name : |
Mr. Hemant Mohan Anavkar |
|
Designation : |
Director |
|
Address : |
Ghar, Swami Samarth Nagar, Andheri (W), Mumbai – 400053, |
|
Date of Birth/Age : |
17.02.1962 |
|
Date of Appointment : |
15.12.2000 |
|
|
|
|
Name : |
Ms. Manisha Hemant Anavkar |
|
Designation : |
Director |
|
Address : |
Ghar, Swami Samarth Nagar, Andheri (W), Mumbai – 400053, |
|
Date of Birth/Age : |
07.02.1968 |
|
Date of Appointment : |
15.12.2000 |
|
|
|
|
Name : |
Ms. Naseem Ahsan Khan |
|
Designation : |
Director |
|
Address : |
Society Limited, New |
|
Date of Birth/Age : |
12.11.1954 |
|
Date of Appointment : |
15.12.2000 |
|
|
|
|
Name : |
Mr. Arif Ahsan Khan |
|
Designation : |
Director |
|
Address : |
209, 7/C, Al Aman Apartment, Amrut Nagar, Oshiwara Garden Road,
Jogeshwari (W), Mumbai – 400102, Maharashtra, India. |
|
Date of Birth/Age : |
13.05.1971 |
|
Date of Appointment : |
16.08.2001 |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
AS ON 30.09.2010
|
Names of Shareholders |
No. of Shares |
|
Aasif Ahsan Khan |
1939000 |
|
Hemant Mohan Anavkar |
346250 |
|
Manisha Hemant Anavkar |
346250 |
|
Naseem Ahsan Khan |
138500 |
|
TOTAL |
2770000 |
AS ON 30.09.2010
|
Equity Share
Breakup |
|
Percentage of
Holding |
|
Category |
|
|
|
Directors or relatives of directors |
|
100.00 |
|
|
Total
|
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of clean room equipments, pre – fabricated panels and
injectable lines. |
|
|
|
PRODUCTION STATUS AS ON 31.03.2009
|
Particulars |
Unit |
|
|
Installed
Capacity |
|
Modular Panel |
Sq mtr |
|
|
100000 |
GENERAL INFORMATION
|
Customers : |
|
||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
|
No. of Employees : |
Information not divulged by management |
||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
|
Bankers : |
Dena Bank, 67-A, Krishna Bhavan, Nehru Road, Vile Parle(E), Mumbai – 400057,
Maharashtra, India |
||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
|
Facilities : |
NOTES:
|
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
Deloitte Haskins and Sells Chartered Accountant |
|
Address : |
Heritage, 3rd Floor, Near Gujarat Vidyapeth, Off |
|
Tel. No.: |
91-79-27582542/27582543 |
|
Fax No.: |
91-79-27582551 |
|
|
|
|
Associates/Subsidiaries : |
|
CAPITAL STRUCTURE
AS ON 31.03.2010
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
5000000 |
Equity Shares |
Rs. 10 each |
Rs.50.000 millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
2770000 |
Equity Shares |
Rs. 10 each |
Rs.27.700
millions |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
27.700 |
27.700 |
27.700 |
|
|
2] Share Application Money |
8.836 |
8.836 |
8.836 |
|
|
3] Reserves & Surplus |
156.581 |
59.687 |
32.618 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
193.117 |
96.223 |
69.154 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
64.962 |
88.694 |
24.523 |
|
|
2] Unsecured Loans |
0.000 |
0.000 |
0.000 |
|
|
TOTAL BORROWING |
64.962 |
88.694 |
24.523 |
|
|
DEFERRED TAX LIABILITIES |
0.000 |
0.000 |
0.339 |
|
|
|
|
|
|
|
|
TOTAL |
258.079 |
184.917 |
94.016 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
66.405 |
47.512 |
45.755 |
|
|
Capital work-in-progress |
9.973 |
10.701 |
0.030 |
|
|
|
|
|
|
|
|
INVESTMENT |
1.805 |
1.453 |
1.454 |
|
|
DEFERREX TAX ASSETS |
1.625 |
0.053 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
80.249
|
62.836 |
68.829 |
|
|
Sundry Debtors |
263.891
|
174.531 |
124.990 |
|
|
Cash & Bank Balances |
74.419
|
80.817 |
7.345 |
|
|
Other Current Assets |
0.000
|
0.000 |
0.000 |
|
|
Loans & Advances |
46.536
|
51.903 |
27.744 |
|
Total
Current Assets |
465.095
|
370.087 |
228.908 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
121.159 |
77.420 |
98.941 |
|
|
Other Current Liabilities |
132.376
|
156.957 |
72.494 |
|
|
Provisions |
33.289
|
10.815 |
18.942 |
|
Total
Current Liabilities |
286.824
|
245.192 |
190.377 |
|
|
Net Current Assets |
178.271
|
124.895 |
38.531 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.303 |
8.246 |
|
|
|
|
|
|
|
|
TOTAL |
258.079 |
184.917 |
94.016 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
657.194 |
444.413 |
293.233 |
|
|
|
Other Income |
16.750 |
4.320 |
|
|
|
|
TOTAL (A) |
673.944 |
448.733 |
293.233 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Purchase of Traded goods |
58.625 |
26.996 |
|
|
|
|
Raw Materials consumed |
267.657 |
213.333 |
|
|
|
|
Manufacturing and other expenses |
27.484 |
17.873 |
NA |
|
|
|
Personnel Expenses |
54.248 |
38.111 |
|
|
|
|
Selling and Distribution Expenses |
40.082 |
28.407 |
|
|
|
|
Administrative and General Expenses |
59.082 |
58.166 |
|
|
|
|
Variation In Stock |
(1.481) |
0.475 |
|
|
|
|
TOTAL (B) |
505.697 |
383.361 |
|
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
168.247 |
65.372 |
NA |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
11.340 |
6.651 |
NA |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
156.907 |
58.721 |
44.816 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
9.086 |
7.111 |
7.483 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
147.823 |
51.610 |
37.333 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
50.929 |
24.542 |
13.558 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-H) (I) |
96.894 |
27.068 |
23.775 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
59.687 |
32.618 |
|
|
|
|
|
|
|
|
|
|
|
BALANCE CARRIED
TO THE B/S |
156.581 |
59.686 |
NA |
|
|
|
|
|
|
|
|
|
|
EARNINGS IN
FOREIGN CURRENCY |
|
|
|
|
|
|
|
Export Earnings |
220.721 |
85.496 |
|
|
|
TOTAL EARNINGS |
220.721 |
85.496 |
NA |
|
|
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
|
|
Raw Materials |
65.535 |
40.538 |
|
|
|
|
Capital Goods |
1.078 |
9.211 |
|
|
|
|
Finished Goods |
27.522 |
5.918 |
|
|
|
TOTAL IMPORTS |
94.135 |
55.667 |
NA |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
34.98 |
9.77 |
NA |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
PAT / Total Income |
(%) |
14.37
|
6.03 |
4.62 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
22.49
|
11.61 |
-- |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
27.81
|
12.35 |
13.59 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.76
|
0.53 |
0.53 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
1.82
|
3.46 |
3.10 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
1.62
|
1.50 |
1.20 |
LOCAL AGENCY FURTHER INFORMATION
FINANCIAL
HIGHLIGHTS
- During the financial year, the Company recorded 47.88% growth in sales over previous ear on account of robust growth in domestic as well as overseas projects.
- EBITDA grew to 24.96% from 14.57% during the year .
- PAT
grew to 14.38% from 6.03% during the year .
Business Review
The underlying philosophy followed by the company is that of simplification of complex problems. Be it a design complexity, or an engineering conundrum, or even a resource management problem, the company’s team of managers, designers, engineers and R and D artists leave no stone unturned to simplify the complexities.
The company has introduced revolutionary yet simple solutions to the pharmaceutical and biotech industries over the past decade. The erstwhile cumbersome brick and mortar was first simplified into modular panels to undertake internal infrastructure. The prevalent clean room systems are being shrunk and simplified to offer containment solutions. Once again, the outer box technology has been simplified with a radical new technology, “Plaswall”, a construction system that is bound to revolutionise the future of construction.
Having proven the mettle in hi‐tech construction for the pharmaceutical industry all over the emerging markets, the company’s experience in the sector has prompted us to broad‐base into external box technology of construction. This technology is proving to be highly efficient in time, cost and strength. It is the technology of the future. The company is in the process of introducing a brand new patented Plaswall technology for the construction industry. The test marketing of Plaswalls has been received extremely well by the construction industry. This is the technology that could well be the most viable solution to the urbanisation challenges of the
developing world.
They aim to further consolidate into pharma and biotech
industries, becoming turnkey solutions provider with containment solutions, and
inner and outer construction solutions. They will concurrently continue
creating visibility in other sectors for Plaswall by appointing franchises in
Business Operation Analysis
The company’s business in on increasing trend and
successfully capturing market share in
The company’s R and D Team has successfully completed
development of HID Conjugate Vaccine technology for
As a part of simplification, the company has taken several initiatives to overcome complexity of construction by diversifying the business into External Construction with an innovative technique in form of ‘Plaswall’.
The Directors believes that challenges face by Parma Sector will continue way ahead and the company is no exception to these challenges. However, with the strong and growing customer base, a robust risk management and teamwork, we are confident that the company is poised to outperform it pears in the medium to long term to establish itself a model by diversifying into external infrastructure projects and affordable, yet reliable housing solutions.
Subsidiaries
- On 18.02.2010, the company has incorporated a subsidiary under the name and style of Firox Technologies Private Limited. It will be one of the leading manufacturing companies in specialized doors – flush doors, fire doors and commercial doors for the real estate industries and allied industries. It will provide complete turnkey service from concept to commissioning.
- On 11.06.2010 the company has incorporated a subsidiary under the name and style of Fabtech Sterling Building Technologies Private Limited. It will be engaged in specialty construction activities.
- On 26.03.2010 the company has incorporated a subsidiary under the name and style of Fab Entertainment Private Limited. It will be engaged in entertainment business especially of production of movies.
- On 02.08.2010 the company has incorporated a subsidiary under the name and style of Transnational Exim Private Limited. It will be engaged in Sourcing and Supplying of Engineering Products for non-pharma Industry.
- On 4th August, 2010 the company has incorporated a Limited liability partnership firm under the name and style of Fabtech Silisbuild Systems LLP. It will be engaged in Trading activities of “plaswall” products for the Government projects.
FORM 8
|
Name of the company |
FABTECH
TECHNOLOGIES INTERNATIONAL PRIVATE LIMITED |
|
Presented By |
Union Bank Of |
|
1) Date and description of instrument creating the change |
S-3 Hypothecation
(Goods) Agreement Dated: 17th March, 2004 |
|
2) Amount secured by the charge/amount owing on the securities of charge |
Rs.1.500
millions. |
|
3) Short particular of the property charged. If the property acquired is subject to charge, date of the acquired of the property should be given |
Hypothecation of
goods I stocks under Import belonging to the Borrower which now or
hereinafter from) time to time during this security shall be brought’ in,
stored or be in or about the Borrower’s premises or godown/s at 19- 21,
Ashapura Industrial Estate, Walvi Naka, Vasai(East) and / or in transit or
with Borrower’s Agents or wherever else (e may be. |
|
4) Gist of the terms and conditions and extent and operation of the charge. |
The security as
stated in item No.3 above has been taken to secure
Import LIC (DA 90 days) limit of Rs.1.500 millions granted by the Bank to the
Company. Margin : 25%. |
|
5) Name and Address and description of the person entitled to the charge. |
Union Bank of |
|
6) Date and brief description of instrument modifying the charge |
NA |
|
7) Particulars of modifications specifying the terms and conditions or the extent of operations of the charge in which modification is made and the details of the modification. |
NA |
|
This form is for |
Modification of charge |
|
Charge
identification number of the modified |
10025445 |
|
Corporate
identity number of the company |
U24230MH1995PTC094603 |
|
Name of the
company |
FABTECH
TECHNOLOGIES INTERNATIONAL PRIVATE LIMITED |
|
Address of the registered
office or of the principal place of
business in |
717, Janki Centre, Off Veera Desai Road, Andheri (W), Mumbai – 400053,
Maharashtra |
|
Type of charge |
Immovable
Property |
|
Particular of
charge holder |
Dena Bank, 67-A, Krishna Bhavan, Nehru Road, Vile Parle(E), Mumbai –
400057, Maharashtra, India |
|
Nature of
description of the instrument creating or modifying the charge |
Memorandum Of
Entry |
|
Date of
instrument Creating the charge |
16.12.2008 |
|
Amount secured by
the charge |
Rs.117.211
millions |
|
Brief particulars
of the principal terms an conditions and extent and operation of the charge |
Rate of Interest As per
respective agreed rates in respect of
diverse credit facilities rates Terms of Repayment
Not Applicable Margin As per
respective agreed rates in respect of
diverse credit facilities rates Extent and
Operation of the charge Equitable
Mortgage by deposit of Title Deeds in respect of Company's immovable Properties
at 1) Unit No.19, 20 and 21 admn.431.49 Sq. Mtrs. Ashapura Industrial Estate,
Gupat Compound, Near Walvadevi Temple, Waliv, Vasai (West), Dist. Thane 2)
Plot no.24 admn. 1000 Sq. Mtrs. in Others Equitable
Mortgage by deposit of Title deeds in respect of Company's immovable
properties to secure repayment and discharge by the company of its
liabilities in respect of diverse credit facilities not exceeding Rs.117.211
Millions granted to the company by Dena Bank, Vile Parle (East) branch
together with interest thereon at the respective agreed rates, compound
interest, further/ penal interest in case of default, liquidated damages,
commitment charges, premium on prepayment or on redemption etc. |
|
Short particulars
of the property charged |
Equitable
Mortgage by deposit of Title Deeds in respect of Company's immovable
Properties at 1) Unit No.19, 20 and 21 admn.431.49 Sq. Mtrs. Ashapura
Industrial Estate, Gupat Compound, Near Walvadevi Temple, Waliv, Vasai
(West), Dist. Thane 2) Plot no.24 admn. 1000 Sq. Mtrs. in |
|
Particulars of
the present modification |
By the Present
Modification Dated 16-12-2008 the Borrower has extended the existing Mortgage
on the same Immovable Properties as mentioned in Point no.14 to cover the revised/enhanced
limit from Rs.79.400 Millions to Rs.117.211 Millions. Thus by Present
Modification, the total limit stands at Rs.117.211 Millions |
FIXED ASSETS
- Plant and Machinery
- Vehicles
- Computers
WEBSITE DETAILS
PROFILE
Subject Established in 1999, Fabtech is a hi-tech engineering and infrastructure company designing and offering innovative building (so far internal construction) and containment solutions to pharma and biotech industry.
- Company has a mission to make things simple (technology development for simplifying things is not easy), company has introduced revolutionary yet simple solutions to the industry, which is developed and manufactured in-house in state of art manufacturing facilities over the last eight years.
- It is one of the leading manufacturer of pre-engineered, pre-fabricated modular partitions/panels and doors for building infrastructure. Recently diversified into manufacturing of value engineered and economical internal panels, sold under brand ‘Fabtec Lite’ for non-pharma end markets.
- The Company also designs, fabricates, integrates, installs and services highly technical custom built Isolation/Containment Systems for pharmaceutical and biotech industry and is preparing for nuclear applications.
- Modular inner construction for pharma and non pharma application (replacing brick and mortar) and containment solutions for hi-tech drug production i.e. cytotoxics, nuclear medicine, biomedicines (import substitute) are the products, company has successfully introduced in the market against stiff mindset.
- In order to broaden its revenue base, company plans to undertake construction of outer boxes along with inner construction (beginning with pharma and biotech sector), It has entered into a technical joint venture with Philippines based Sterling Construction and Developments Pvt. Ltd. to manufacture its patented building system “Plaswall” which is hugely successful in Australia, Philippines and Qatar.
- Company
has a strong presence in the overseas markets such as Middle East,
- Export revenues estimated to account for ~33% of total revenue in FY09.
- Company has a total employee strength of 308 people including strong engineering and design team of about 32 engineers.
- The Company has following certification and approval for its modular panels:
- Only
company in
- Only
company in
- Approved vendor by Defense.
- Key customers includes reputed companies like PFIZER, RANBAXY, AUROBINDO, RELIANCE, LUPIN, STRIDES, among others in pharma and BOSCH, VOLKSWAGEN, COLGATE for non pharma.Furthermore in a short period of time, the Company has been able to successfully acquire some large customers such as Sandoz, Strides, Dr Reddy’s, Panacea Biotech, Ranbaxy, etc for both its Isolation systems and modular panels for non-pharma.
- To
penetrate the developed markets like
Press Release:
Fabtech
Technologies bags Multi million dollar projects from Syria,
Announcement /
Corporate 01.11.2010, 19:25 IST
Fabtech Technologies International Private Limited, the company
providing complete manufacturing solutions has bagged two very prestigious
multi million dollar biotech turnkey construction projects in
Fabtech has been awarded the Syrian project on turnkey basis which
includes conceptual design, basic engineering, detailed engineering, supply of
fill finish machines, sterile vessels with magnetic stirrers , transfer piping
with complete automation right from charging, filtration and holding to the
filling buffer tank, programmed cip system to work without any manual
intervention, laminar flow units flushed to the ceiling, autoclaves, inner
walls in sandwich modular clean room paneling system , heating ventilation and
air-conditioning with complete building management system automation for
temperature, relative humidity and pressure. The scope also includes complete
utility piping for purified water, water for injection, pure steam, compressed
air, nitrogen storage and distribution system along with Installation,
validation and commissioning the entire plant.
Asia Pharmaceutical Industries (API) is one of the pioneering
distinctive pharmaceutical companies in
Germany-based Medical Aid Organisation, Action Medeor handed over its
Tanzanian project on a turnkey basis to Fabtech among six international bidders
for Design, Planning, Supply and Execution of a Solid Dosage Pharmaceutical
Plant in
The scope of work for the pharma unit in
Aasif Khan, Director, Fabtech Technologies International Private Limited
says, "Fabtech Technologies is committed to providing total solutions in
the area of pharmaceutical and biotechnology facility design and execution. We
have been designing and constructing sophisticated clean rooms for pharma
companies for several years. The Syrian project is another feather in our cap.
The Syrian project is for a formulation facility for 5 filling and packing
lines which are completely segregated to facilitate filling of multi products at
one time"
Fabtech Technologies International is in the business of manufacturing
innovative products for the pharmaceutical sector, with internationally
acclaimed and certified technology. With an array of products to choose from
and an extensive marketing reach, Fabtech has made its presence felt in
About Fabtech
Technologies International Private
Fabtech Technologies International Private Limited designs and builds
Pharmaceutical and Biotech facilities internationally. In its 14 years of
existence, Fabtech has executed more than 75 projects spread across 20
countries. Fabtech has built an excellent infrastructure to manufacture
pre-fabricated and pre-engineered modular panels (inner construction),
Isolation and Containment solutions and clean air equipment including
Sterilizing Tunnels which it supplies in the Indian and international market.
Fabtech is a leading player in the Indian Cleanrooms market for modular
panels and doors with a market share of about 25%. Already active in the Middle
East, Persian Gulf and Africa and Afro Arab countries, with certification from
Warrington Fire, Fabtech has forged alliances in North America, Europe, Latin
America and
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals have
been formally charged or convicted by a competent governmental authority for
any financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.44.78 |
|
|
1 |
Rs.73.42 |
|
Euro |
1 |
Rs.65.27 |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
5 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
5 |
|
--PROFITABILIRY |
1~10 |
5 |
|
--LIQUIDITY |
1~10 |
5 |
|
--LEVERAGE |
1~10 |
5 |
|
--RESERVES |
1~10 |
5 |
|
--CREDIT LINES |
1~10 |
5 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
45 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.